Compare · MITQ vs TMO
MITQ vs TMO
Side-by-side comparison of Moving iMage Technologies Inc. (MITQ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MITQ operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $172.66B, about 32193.2x MITQ ($5.4M).
- Over the past year, MITQ is down 30.5% and TMO is up 16.9% - TMO leads by 47.4 points.
- TMO has hit the wire 6 times in the past 4 weeks while MITQ has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for MITQ).
- Company
- Moving iMage Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.57-2.68%
- $464.76+0.67%
- Market cap
- $5.4M
- $172.66B
- 1M return
- -7.28%
- +3.73%
- 1Y return
- -30.54%
- +16.86%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MITQ
- Moving iMage Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Moving iMage Technologies Inc.
- Moving iMage Technologies Reports Revenue of $3.39M for Seasonally Soft Q3, Bolstered by DCS Cinema Loudspeaker Shipments; Hosts Call Today at 11am ET
- Moving iMage Technologies Hosts Third Quarter Fiscal 2026 Conference Call May 14, 2026 at 11am ET
- Moving iMage Technologies Names Bart Bedard as CFO
- Moving iMage Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moving iMage Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Moving iMage Showcases DCS Cinema Loudspeaker and LEA Amplifier PLF Lines at CinemaCon Booth 427J; Hosts Investor Open House April 15th
- Moving iMage Secures Three Year DCS Cinema Loudspeaker Commitment with Alamo Drafthouse Cinema and Launches Auditorium Upgrades at Two Locations
- Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium
Latest TMO
- Piper Sandler initiated coverage on Thermo Fisher with a new price target
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)